Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7528794 | 1.00 | LMNA (0.50) | LMNAPOLBGRM2MEN1KMT2A | |
| SCHEMBL7526398 | 0.88 | GRM2 (0.51) | LMNAPOLBGRM2MEN1KMT2A | |
| SCHEMBL7244999 | 0.86 | GRM2 (0.47) | LMNAPOLBGRM2MEN1KMT2A | |
| SCHEMBL7513335 | 0.83 | ADRB3 (0.54) | LMNAPOLBGRM2MEN1KMT2A | |
| SCHEMBL7518593 | 0.83 | ADRB3 (0.54) | LMNAPOLBGRM2MEN1KMT2A | |
| SCHEMBL5194363 | 0.82 | GRM2 (0.44) | LMNAPOLBGRM2MEN1KMT2A | |
| SCHEMBL27557792 | 0.82 | GRM2 (0.46) | LMNAPOLBGRM2MEN1KMT2A | |
| SCHEMBL7623436 | 0.82 | GRM2 (0.44) | LMNAPOLBGRM2MEN1KMT2A | |
| SCHEMBL7530130 | 0.82 | GRM2 (0.44) | LMNAPOLBGRM2MEN1KMT2A | |
| SCHEMBL5196623 | 0.82 | GRM2 (0.44) | LMNAPOLBGRM2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | ASAHI-KASEI KABUSHIKI KAISHA (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1238973-A1 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-09-11 | — | — | EP | disclosed |
| EP-1195371-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | CPT1A, CBR1, NR1H3 | LMNA 3664/4885POLB 3133/4885GRM2 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.